Journal of Clinical Psychopharmacology

Publication Venue For
- Severe Extrapyramidal Symptoms in a Patient with Niemann-Pick Type C Disease After a Long-Acting Injection of Risperidone. 39:677-678. 2019
- The Impact of Medication Anticholinergic Burden on Cognitive Performance in People With Schizophrenia.. 37:651-656. 2017
- Divalproex in the treatment of posttraumatic stress disorder: a randomized, double-blind, placebo-controlled trial in a veteran population.. 28:84-88. 2008
- Reply to Dr Ng's comments on "A Randomized, Double-Blind, Placebo-Controlled Trial of Augmentation with An Extended Release Formulation of Methylphenidate in Outpatients with Treatment-Resistant Depression" [11]. 28:117-118. 2008
- Standard and higher dose of olanzapine in patients with schizophrenia or schizoaffective disorder: A randomized, double-blind, fixed-dose study. 28:392-400. 2008
- Lamotrigine as add-on therapy in schizophrenia: results of 2 placebo-controlled trials.. 27:582-589. 2007
- Effectiveness of low-dose naltrexone in the post-detoxification treatment of opioid dependence.. 27:468-474. 2007
- A placebo-controlled trial of bupropion SR in the treatment of chronic posttraumatic stress disorder.. 27:193-197. 2007
- Motor cortex excitability after vagus nerve stimulation in major depression.. 27:156-159. 2007
- The efficacy and tolerability of tiagabine in adult patients with post-traumatic stress disorder.. 27:85-88. 2007
- A randomized, double-blind, placebo-controlled trial of augmentation with an extended release formulation of methylphenidate in outpatients with treatment-resistant depression.. 26:653-656. 2006
- Erratum: Modafinil for atypical depression: Effects of open-label and double-blind discontinuation treatment (Journal of Clinical Psychopharmacology (August 2006) 26, (373-378)). 26:473. 2006
- Erratum: Modafinil for atypical depression: Effects of open-label and double-blind discontinuation treatment (Journal of Clinical Psychopharmacology (August 2006) 26, (373-378)). 26:523. 2006
- Modafinil for atypical depression: Effects of open-label and double-blind discontinuation treatment (vol 26, pg 373, 2006). 26:523-523. 2006
- Modafinil for atypical depression: effects of open-label and double-blind discontinuation treatment.. 26:373-378. 2006
- Venlafaxine extended release in posttraumatic stress disorder: a sertraline- and placebo-controlled study.. 26:259-267. 2006
- Pharmacokinetics and clinical effects of multidose sublingual triazolam in healthy volunteers.. 26:4-8. 2006
- The efficacy of olanzapine for decreasing cue-elicited craving in individuals with schizophrenia and cocaine dependence: a preliminary report.. 26:9-12. 2006
- Effects of paroxetine and venlafaxine XR on heart rate variability in depression.. 25:480-484. 2005
- Open-label pilot study of ziprasidone for refractory generalized anxiety disorder.. 25:497-499. 2005
- Treatment of depression in the medically ill.. 25:S14-S18. 2005
- Hyperforin plasma level as a marker of treatment adherence in the National Institutes of Health Hypericum Depression Trial.. 25:243-249. 2005
- Maintenance therapy with fluoxetine in posttraumatic stress disorder: a placebo-controlled discontinuation study.. 25:166-169. 2005
- Acute dystonic reaction with moderate-dose ziprasidone.. 24:563-564. 2004
- Efficacy of the novel anxiolytic pregabalin in social anxiety disorder: a placebo-controlled, multicenter study.. 24:141-149. 2004
- Fluvoxamine-controlled release formulation for the treatment of generalized social anxiety disorder.. 24:118-125. 2004
- Overt Aggression and Psychotic Symptoms in Patients with Schizophrenia Treated with Clozapine, Olanzapine, Risperidone, or Haloperidol. 24:225-228. 2004
- Bipolar disorder and crossover design.. 23:319-320. 2003
- Bipolar Disorder and Crossover Design: Reply to Curtin Letter. 23:320. 2003
- Antipsychotic-induced weight gain and therapeutic response: a differential association.. 22:244-251. 2002
- New designs for studies of the prophylaxis of bipolar disorder.. 22:1-3. 2002
- St. John's wort in generalized anxiety disorder: three case reports.. 21:635-636. 2001
- Pharmacokinetics and clinical effects of sublingual triazolam in pediatric dental patients.. 21:268-272. 2001
- A preliminary study of bupropion sustained-release for smoking cessation in patients with chronic posttraumatic stress disorder.. 21:94-98. 2001
- Mecamylamine increases cigarette smoking in psychiatric patients.. 20:706-707. 2000
- Preferential cerebrospinal fluid acetylcholinesterase inhibition by rivastigmine in humans.. 19:513-521. 1999
- Treatment of social phobia with gabapentin: a placebo-controlled study.. 19:341-348. 1999
- Case report: possible neuroleptic malignant syndrome associated with olanzapine.. 18:485-486. 1998
- Discontinuation of clonazepam in the treatment of social phobia.. 18:373-378. 1998
- Fluvoxamine in civilians with posttraumatic stress disorder.. 18:93-95. 1998
- Moclobemide in social phobia: a controlled dose-response trial.. 17:247-254. 1997
- A multicenter, double-blind comparison of the effects of nefazodone and fluoxetine on sleep architecture and quality of sleep in depressed outpatients.. 17:161-168. 1997
- Pharmacokinetics of oral triazolam in children.. 17:169-172. 1997
- Desipramine versus phenelzine in recurrent unipolar depression: clinical characteristics and treatment response.. 17:78-83. 1997
- Trial of trazodone for posttraumatic stress disorder using a multiple baseline group design.. 16:294-298. 1996
- Fluvoxamine versus clomipramine for obsessive-compulsive disorder: a double-blind comparison.. 16:121-129. 1996
- Paroxetine as a treatment for premenstrual dysphoric disorder.. 16:3-8. 1996
- Monitoring of clozapine blood levels in the real world [10]. 16:90-91. 1996
- Palinacousis after closed-head injury in a patient with schizophrenia [13]. 16:94-. 1996
- Severe parkinsonian symptom development on combination treatment with tacrine and haloperidol.. 15:284. 1995
- Nicotine skin patch treatment and adverse reactions: skin irritation, skin sensitization, and nicotine as a hapten.. 15:145-146. 1995
- Reply. 15:146-146. 1995
- Long-term safety and clinical acceptability of venlafaxine and imipramine in outpatients with major depression.. 14:322-329. 1994
- Adinazolam sustained-release treatment of panic disorder: a double-blind study.. 14:255-263. 1994
- Nicotine skin patch treatment increases abstinence, decreases withdrawal symptoms, and attenuates rewarding effects of smoking.. 14:41-49. 1994
- Treatment of social phobia with clonazepam and placebo.. 13:423-428. 1993
- William W.K. Zung, MDiv, MS, MD. 12:234-234. 1992
- Haase hermeneutics, or, the exegesis of the neuroleptic threshold.. 12:64-65. 1992
- Syndrome of inappropriate antidiuretic hormone secretion.. 12:68-69. 1992
- Delayed onset of neuroleptic malignant syndrome after discontinuation of thioridazine.. 10:146. 1990
- Dexamethasone suppression test status does not predict differential response to nortriptyline versus amitriptyline.. 8:421-425. 1988
- The response of depressed inpatients to isocarboxazid.. 8:100-107. 1988
- Symptom exacerbation in psychotically depressed adolescents due to high desipramine plasma concentrations.. 6:161-164. 1986
- The effects of isocarboxazid on blood pressure and pulse.. 6:139-143. 1986
- Behavioral toxicity with alprazolam. 4:294. 1984
- Recommendations for depression publications.. 3:205-206. 1983
- Lack of efficacy of a new antidepressant (bupropion) in the treatment of panic disorder with phobias.. 3:28-31. 1983
- Relapse, side effects, and monoamine oxidase inhibition during long term use of isocarboxazid: a case report.. 3:42-43. 1983
- Lack of efficacy of a new antidepressant (bupropion) in the treatment of panic disorder with phobias. 3:28-31. 1983
- Lack of efficacy of a new antidepressant (bupropion) in the treatment of panic disorder with phobias. 3:63-69. 1983
- Failure of isocarboxazid and haloperidol to alleviate delusional depression in a pilot study.. 2:408-411. 1982
- Loss of appetite and weight associated with the monoamine oxidase inhibitor isocarboxazid.. 2:263-266. 1982
- Treatment of spasmodic torticollis with ethyl chloride.. 2:286. 1982
- Adding a tricyclic antidepressant to a monoamine oxidase inhibitor.. 2:216. 1982
- Early and late side effects of phenelzine.. 2:208-210. 1982
- Letters to the editors. 2:286. 1982
- Loxapine in psychogeriatrics: A placebo- and standard-controlled clinical investigation. 2:122-126. 1982
- Cocaine and amphetamine use in patients with psychiatric illness: a randomized trial of typical antipsychotic continuation or discontinuation. 2003

Publication Venue For